2012年 IAAO

国際フォーラム2012(IAAO2012)

Theme:The Dynamism of Therapeutic Strategy from the New Oncology Paradigm

Opening Remarks

201201 Osamu Nagayama, Chairman
Chugai Academy for Advanced Oncology

1. New Molecular Targets

▶ Immune Checkpoint Blockade in Cancer Immunotherapy

201202
Speaker:
James P. Allison, PhD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Ryuzo Ueda, MD, PhD 
Aichi Medical University, Japan
201203

▶ Chemokine Receptor 4 (CCR4) is a Promising Target for Development of New Tumor Immunotherapy

Speaker:
Ryuzo Ueda, MD, PhD
Aichi Medical University, Japan
Chair:
Makoto Ogawa, MD
Emeritus President, Aichi Cancer Center, Japan

▶ Targeting the Hedgehog Pathway in Medulloblastoma

201206
Speaker:
Thomas Curran, PhD, FRS
The University of Pennsylvania, USA
Chair:
Nobuyuki Mizunuma, MD
Cancer Institute Hospital, JFCR, Japan
201230

2. Rationale for combination of molecular targeted agent

▶ Acquired and Adaptive Resistance to Targeted Therapy

201231
Speaker:
Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Chikashi Ishioka, MD
Tohoku University, Japan
201207

▶ Combinatorial Approaches against PI3 Kinase Pathway

201208
Speaker:
José Baselga, MD, PhD
Massachusetts General Hospital, USA
Chair:
Masakazu Toi, MD, PhD
Kyoto University, Japan
201209

3. New Molecular Class

▶ Antibody Drug Conjugates for Cancer Therapy

201210
Speaker:
Paul Polakis, PhD
Genentech Inc, USA
Chair:
Mitsuaki Yoshida, PhD
Cancer Chemotherapy Center, JFCR, Japan
201211

4. Drug Resistances

▶ Challenges with Drug Resistance

201212
Speaker:
Jeffrey A. Engelman, MD, PhD
Massachusetts General Hospital, USA
Chair:
Nagahiro Saijo,MD, PhD
Japanese Society of Medical Oncology, Japan
201213

▶ Sensitivity and Resistance to Targeting FGFR in Cancer

201214
Speaker:
Nicholas Turner, MD, PhD
The Royal Marsden, UK
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, JFCR, Japan
201215

5. Advances and Challenges in Tumor Therapy

▶ Prostate Cancer(Canceled)

Speaker:
Howard I . Scher, MD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Chikashi Ishioka, MD
Tohoku University, Japan

▶ The Treatment of Colorectal Cancer in the Era of Molecular Characterization

201216
Speaker:
Josep Tabernero, MD, PhD
Vall d’Hebron University Hospital, Spain
Chair:
Yuko Kitagawa, MD, PhD
Keio University, Japan
201217

▶ The Evolution to Genomic Testing and Targeted Therapy as Standard of Care for Lung Cancer

201218
Speaker:
Bruce E . Johnson, MD
Dana-Farber Cancer Institute, USA
Chair:
Hiroyuki Mano, MD, PhD
Jichi Medical University/The University of Tokyo, Japan
201219

6. Impact of Oncology New Paradigm on patients

▶ Drug Development and Approval in the Age of Molecular Targeting and “Precision” Therapy

201220
Speaker:
Bruce A. Chabner, MD
Massachusetts General Hospital, USA
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, JFCR, Japan
201221

▶ Strategy and Development in Asian Clinical Trials

201222
Speaker:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, JFCR, Japan
Chair:
Patrick G. Johnston, MD, PhD
Queen’s University of Belfast, UK
201223

▶ Value-based Medicine – a UK and European Perspective

201224
Speaker:
Patrick G. Johnston, MD, PhD
Queen’s University of Belfast, UK
Chair:
Bruce A. Chabner, MD
Massachusetts General Hospital, USA
201225
一般社団法人 中外Oncology学術振興会議